Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q1 2023 Earnings Conference Call May 8, 2023 4:30 PM ET Company Participants Jonae Barnes - Senior Vice President of Investor Relations and Corporate Communications Jean-Pierre Sommadossi - Founder and Chief Executive Officer Andrea Corcoran - Financial Officer and Executive Vice President of Legal Janet Hammond - Chief Development Officer Conference Call Participants Maxwell Skor - Morgan Stanley Jonathan Miller - Evercore ISI Tim Lugo - William Blair Operator Good ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number: 001-39661 ATEA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware ...

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2022 Earnings Conference Call February 28, 2023 4:30 PM ET Company Participants Jonae Barnes - Senior VP, Investor Relations & Corporate Communications Jean Sommadossi - Founder, Chairman & CEO Andrea Corcoran - CFO & Executive VP, Legal Janet Hammond - Chief Development Officer Arantxa Horga - Chief Medical Officer Conference Call Participants Roanna Ruiz - SVB Leerink Jessica Hui - Evercore Operator Good afternoon, ladies and gentlemen. Welcome to the Atea Pharm ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39661 ATEA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its Charter) Delaware 46-0574869 (State or other jurisdict ...

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q3 2022 Earnings Conference Call November 7, 2022 4:30 PM ET Company Participants Jonae Barnes - SVP, IR & Corporate Communications Jean-Pierre Sommadossi - CEO and Founder John Vavricka - CCO Janet Hammond - CDO Andrea Corcoran - CFO and Executive President, Legal Conference Call Participants Hannah Adeoye - JPMorgan Matthew Harrison - Morgan Stanley Umer Raffat - Evercore Tim Lugo - William Blair Nik Gasic - SVB Securities Operator Good afternoon, ladies and gentle ...

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Jonae Barnes - Senior Vice President of Investor Relations & Corporate Communications Jean-Pierre Sommadossi - Chief Executive Officer & Founder Janet Hammond - Chief Development Officer Andrea Corcoran - Chief Financial Officer & Executive President of Legal John Vavricka - Chief Commercial Officer Conference Call Participants Tim Lugo - William Blair Nik Gasic - SVB Securities Operator ...

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q1 2022 Earnings Conference Call May 10, 2022 8:00 AM ET Company Participants Jean-Pierre Sommadossi - Founder & CEO Janet Hammond - Chief Development Officer Andrea Corcoran - CFO & EVP, Legal John Vavricka - Chief Commercial Officer Jonae Barnes - SVP, IR & Corporate Communications Conference Call Participants Hannah Colgan - JPMorgan Umer Raffat - Evercore Nik Gasic - SVB Securities Jonathan Miller - Evercore Operator Good morning, and welcome to the Atea Pharmace ...